LIFE - Company ID 0001339970
The table below shows aTYR PHARMA INC's income statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
| Line item | Q1 2026 | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 |
|---|---|---|---|---|---|---|
| Revenue | - | $190.00K | $0.00 | $0.00 | $0.00 | $0.00 |
| Cost of revenue | - | - | - | - | - | - |
| Gross profit | - | - | - | - | - | - |
| R&D | $7.32M | $22.13M | $15.38M | $11.81M | $14.81M | $13.97M |
aTYR PHARMA INC reported annual revenue of $190.00K for fiscal year 2025. That is down 19.1% from $235.00K in fiscal 2024. Over the 7 fiscal years shown, annual revenue declined from $422.00K (FY 2019) to $190.00K. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| SG&A |
| $4.12M |
| $4.80M |
| $4.93M |
| $3.96M |
| $3.34M |
| $3.34M |
| Operating income | -$11.44M | -$26.75M | -$20.31M | -$15.77M | -$18.14M | -$17.32M |
| Income tax | - | - | - | - | - | - |
| Net income | -$10.79M | -$25.74M | -$19.53M | -$14.88M | -$17.26M | -$16.31M |
| EPS (diluted) | -$0.11 | -$0.26 | -$0.22 | -$0.17 | -$0.23 | -$0.23 |